Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03119285 · ClinicalTrials.gov registry record
Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families
A clinical trial of Ovarian Cancer, sponsored by University of Washington.
- Completed
- Registry status
- 34
- Enrollment target
- 1
- Study location
NCT03119285 is a study of Ovarian Cancer that has completed, run by University of Washington. The registered enrollment target is 34 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03119285, a study of Ovarian Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose to test for non-BRCA1/2 mutations in new and existing families with hereditary ovarian cancer in order to better define penetrance and associated malignancies of rare ovarian cancer susceptibility genes. The hypothesis is at least one third of hereditary ovarian carcinoma families wildtype for BRCA1/2 can be solved using an updated version of BROCA (BROCA-HR) that targets 47 genes, including all known ovarian cancer genes and additional candidate genes in related pathways. The objective is to identify families with mutations in rare ovarian cancer susceptibility genes and test both affected and unaffected family members, thereby generating a rough estimate of penetrance for each mutated gene as well as identify new ovarian cancer susceptibility genes. The investigators also plan to enroll self identified African America women, who have been drastically under-represented in clinical cancer genetic testing programs and in OC susceptibility research.
Conditions Studied
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2013-04 |
| Est. Completion | 2022-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03119285
The ClinicalTrials.gov registry entry for NCT03119285 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (95% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03119285 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT03119285 about?
NCT03119285 is a clinical study titled "Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families". The investigators propose to test for non-BRCA1/2 mutations in new and existing families with hereditary ovarian cancer in order to better define penetrance and associated malignancies of rare ovarian cancer susceptibility genes. The hypothesis is at least one third of hereditary ovarian carcinoma f...
What is the current status of trial NCT03119285?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2013-04. Estimated completion is 2022-01-31.
What conditions does trial NCT03119285 study?
This clinical trial studies the following conditions: Ovarian Cancer.
Who is sponsoring clinical trial NCT03119285?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03119285 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.